DLBCL (MYC Rearranged) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About DLBCL (MYC Rearranged)
DLBCL MYC-rearranged is an aggressive subtype of non-Hodgkin lymphoma requiring intensive, often costly, treatment. Facing this diagnosis can be daunting, both medically and financially. TheDrugClub offers a straightforward solution, providing significant savings on essential prescription medications, helping patients access the vital care they need without undue financial burden.
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Within this category, a specific genetic alteration known as "MYC-rearranged" identifies a more aggressive subtype. This rearrangement, often occurring alongside changes in other genes like BCL2 and/or BCL6 (known as 'double-hit' or 'triple-hit' lymphoma), means the cancer cells grow and divide very rapidly. Diagnosing DLBCL MYC-rearranged typically involves a biopsy of the affected lymph node or tissue, followed by specialized genetic testing
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.